Prescription medicine
Ripretinib Brand names: Qinlock
Ripretinib (Qinlock) is a prescription medicine with an FDA approval on record since 2020. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the ripretinib FDA label on DailyMed (effective May 12, 2025, Deciphera Pharmaceuticals, LLC); the NDA 213973 record on Drugs@FDA; every ripretinib label on DailyMed.
Highlights of the record
FDA label of May 12, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageQINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Forms and strengths
- 50 mg
Tablet.
On the market
- Earliest approval on file
- May 15, 2020 Qinlock, Deciphera Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- October 6, 2042 Qinlock tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 5,217 through July 30, 2026
What is ripretinib used for?
From the label: indications and usageQINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
FDA pharmacologic class: Kinase Inhibitor.
Source: FDA drug label (QINLOCK), Deciphera Pharmaceuticals, LLC, effective May 12, 2025 (SPL set 9f18e462-03dd-4296-a02a-a0577e3ee78d), via openFDA; the full label on DailyMed
What does the patient leaflet for ripretinib say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while taking QINLOCK?Your skin may be sensitive to the sun or other forms of light (photosensitivity) during treatment with QINLOCK. Avoid or limit exposure to direct sunlight, sunlamps, and other sources of ultraviolet radiation during treatment and for at least 1 week after stopping treatment with QINLOCK. Use sunscreen and wear clothes that cover your skin if you need to be out in the sun.
From the patient leaflet: How should I store QINLOCK?Store QINLOCK in the original container at room temperature between 68ºF to 77ºF (20ºC to 25ºC). QINLOCK comes with a desiccant packet in the bottle to protect your medicine from moisture. Do not remove the desiccant packet from the bottle. Keep QINLOCK and all medicines out of the reach of children.
Source: FDA drug label (QINLOCK), Deciphera Pharmaceuticals, LLC, effective May 12, 2025 (SPL set 9f18e462-03dd-4296-a02a-a0577e3ee78d), via openFDA; the full label on DailyMed
Is there a generic for ripretinib (Qinlock)?
No generic ripretinib is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 42 patents for Qinlock tablets: the compound patent runs to May 15, 2034, and the last listed entry to October 6, 2042. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2020 earliest approval on file
- 2042 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for ripretinib?
The FDA Adverse Event Reporting System holds 5,217 reports that list ripretinib among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 494 are coded as a death and 1,048 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2025 (1,016, against a median of 303 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other kinase inhibitors
- the pharmacologic class, with prices and generics
- Ripretinib side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other